Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-12-11-Speech-2-163"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20071211.32.2-163"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"In my capacity as rapporteur I am very pleased with the adoption of this report on setting up an Innovative Medicines Initiative Joint Undertaking (IMI).
Implementation of this public/private partnership between the European Federation of Pharmaceutical Industries’ Associations (EFPIA) and the European Commission represents a major promising step forward for large-scale research programmes. The European Commission is duty bound to consider European needs from another angle.
The IMI will have a total budget of EUR 2 billion between 2008 and 2013. The European Commission’s contribution of EUR 1 billion will be disbursed to SMEs and universities. In return, major companies will match this amount with a contribution in kind. They will involve the SMEs and universities by providing them with tools and methodologies to better predict the harmlessness and effectiveness of medicines, intelligent infrastructures and knowledge management.
This cooperation between leading businesses, small-scale research centres, SMEs and universities will help fashion their research projects. IMI will also make improvements to knowledge transfer at universities and in business, and to the involvement of smaller companies in European research."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples